Similarly, Watanabe et al. [14] described circulating cells with a EpCAM+CD44+ phenotype in GC patients, reporting a sensitivity of 92.3%, specificity of 100%, and AUC of 0.974, although specificity and AUC could be questionable because they enrolled only 12 healthy volunteers compared with 26 patients. This evidence concerns the gene EPCAM and gastric cancer.